CV Events in Emetogenic Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

12058 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)

NCT00211601

Chemotherapy Induced Nausea and Vomiting

COMPLETED NA

Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy

NCT04785495

Chemotherapy-induced Nausea and Vomiting

UNKNOWN

Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer

NCT00416689

Breast Cancer Lung Cancer Nausea and Vomiting

COMPLETED

Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy

NCT01661413

Acute Leukemia

COMPLETED

Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting

NCT01993381

Chemotherapy-induced Nausea and Vomiting

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vomiting Cardiovascular Event Arterial Thromboembolic Event

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients enrolled in IHCIS in 2006

HEC or MEC

Intervention Type DRUG

Any HEC or MEC, including aprepitant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HEC or MEC

Any HEC or MEC, including aprepitant

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Enrollment in IHCIS in 2006
* At least one HEC or MEC claim in 2006

Exclusion Criteria

* HEC or MEC claim three months before first HEC/MEC claim - "wash-in" period (i.e. must be enrolled for three months prior to first HEC/MEC claim. For patients whose first HEC/MEC event is between January 1,2006 and March 31, 2006, enrollment criteria for inclusion in the study may extend as far back as October 1, 2005)
* HEC or MEC claims prior to 45 days after last HEC or MEC claim - "wash-out" period. (For patients whose last claim in 2006 was seen after December 1, 2006 enrollment into 2007 to look for further treatment and the 45 day "wash-out" period will be required.)

Eligible Sex

ALL

Accepts Healthy Volunteers

No